S&P Futures
4,293.75 -4.50 (-0.10%) Dow Futures
33,869.00 -4.00 (-0.01%) Nasdaq Futures
13,666.50 -14.75 (-0.11%) Russell 2000 Futures
2,022.70 -1.10 (-0.05%) Crude Oil
88.84 -0.57 (-0.64%) Gold
1,796.00 -2.10 (-0.12%)
Cara Therapeutics, Inc. (CARA)
After hours:
Chart Events
Performance Outlook
| Previous Close | 11.51 |
| Open | 11.46 |
| Bid | 0.00 x 900 |
| Ask | 0.00 x 900 |
| Day's Range | 11.40 - 11.85 |
| 52 Week Range | 7.40 - 18.93 |
| Volume | |
| Avg. Volume | 499,798 |
| Market Cap | 628.14M |
| Beta (5Y Monthly) | 1.08 |
| PE Ratio (TTM) | 24.53 |
| EPS (TTM) | 0.48 |
| Earnings Date | Feb 23, 2022 - Feb 28, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 25.00 |
- Zacks
Cara Therapeutics (CARA) Reports Q2 Loss, Tops Revenue Estimates
Cara (CARA) delivered earnings and revenue surprises of 71.43% and 8.08%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Cara Therapeutics Reports Second Quarter 2022 Financial Results
– Net revenue was $23M for 2Q 2022 comprised of profit-sharing revenue of $8M from KORSUVA™ (difelikefalin) injection and a $15M milestone payment from the European Commission approval of Kapruvia® (difelikefalin) – – KOMFORT Phase 2 trial met primary endpoint in notalgia paresthetica, validating potential broad utility of oral difelikefalin across multiple disease categories; FDA meeting expected in 2H 2022 – – Conference call today at 4:30 p.m. ET – STAMFORD, Conn., Aug. 08, 2022 (GLOBE NEWSWI
- Zacks
Should You Buy Cara Therapeutics (CARA) Ahead of Earnings?
Cara Therapeutics (CARA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
